rs104886456
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM2PP3_ModeratePP5_Very_Strong
The NM_000136.3(FANCC):c.456+4A>T variant causes a splice donor region, intron change. The variant allele was found at a frequency of 0.000172 in 1,556,608 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.00021 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00017 ( 0 hom. )
Consequence
FANCC
NM_000136.3 splice_donor_region, intron
NM_000136.3 splice_donor_region, intron
Scores
2
Splicing: ADA: 0.9997
2
Clinical Significance
Conservation
PhyloP100: 4.61
Genes affected
FANCC (HGNC:3584): (FA complementation group C) The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group C. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PM2
?
Very rare variant in population databases, with high coverage;
PP3
?
Splicing scoreres supports a deletorius effect: Scorers claiming Pathogenic: dbscSNV1_ADA, dbscSNV1_RF, max_spliceai. No scorers claiming Uncertain. No scorers claiming Benign.
PP5
?
Variant 9-95172033-T-A is Pathogenic according to our data. Variant chr9-95172033-T-A is described in ClinVar as [Pathogenic]. Clinvar id is 12045.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr9-95172033-T-A is described in Lovd as [Pathogenic]. Variant chr9-95172033-T-A is described in Lovd as [Pathogenic]. Variant chr9-95172033-T-A is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
|---|---|---|---|---|---|---|---|
| FANCC | NM_000136.3 | c.456+4A>T | splice_donor_region_variant, intron_variant | ENST00000289081.8 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| FANCC | ENST00000289081.8 | c.456+4A>T | splice_donor_region_variant, intron_variant | 1 | NM_000136.3 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.000210 AC: 32AN: 152230Hom.: 0 Cov.: 32
GnomAD3 genomes
?
AF:
AC:
32
AN:
152230
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000287 AC: 72AN: 250510Hom.: 0 AF XY: 0.000273 AC XY: 37AN XY: 135552
GnomAD3 exomes
AF:
AC:
72
AN:
250510
Hom.:
AF XY:
AC XY:
37
AN XY:
135552
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000167 AC: 235AN: 1404378Hom.: 0 Cov.: 25 AF XY: 0.000175 AC XY: 123AN XY: 702208
GnomAD4 exome
AF:
AC:
235
AN:
1404378
Hom.:
Cov.:
25
AF XY:
AC XY:
123
AN XY:
702208
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? AF: 0.000210 AC: 32AN: 152230Hom.: 0 Cov.: 32 AF XY: 0.000188 AC XY: 14AN XY: 74374
GnomAD4 genome
?
AF:
AC:
32
AN:
152230
Hom.:
Cov.:
32
AF XY:
AC XY:
14
AN XY:
74374
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:21Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Fanconi anemia complementation group C Pathogenic:12Other:1
| Pathogenic, no assertion criteria provided | curation | Leiden Open Variation Database | Feb 28, 2020 | Curator: Arleen D. Auerbach. Submitters to LOVD: Arleen D. Auerbach, Daniela Pilonetto. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Jan 01, 2019 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Oct 18, 2021 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 18, 2016 | Variant summary: FANCC c.456+4A>T affects a conserved intronic nucleotide. Mutation Taster predicts a damaging outcome for this variant, and 4/5 Alamut algorithms predict a weaker splice donor site for the variant, which is predicted to increase exon skipping. These in silico predictions are supported by functional studies showing that this variant leads to a truncated protein product. This variant is found in 28/117194 control chromosomes at a frequency of 0.0002389, which does not significantly exceed maximal expected frequency of a pathogenic FANCC allele (0.0017678).The variant has been cited in multiple severe FA patients in homozygous state and in mild FA patients in compound heterozygous state. In addition, multiple clinical diagnostic labs classified this variant as pathogenic. This intronic variant is considered a known common disease variant in the literature, therefore, this is a disease variant and was classified as pathogenic. - |
| Pathogenic, criteria provided, single submitter | research | Department of Pediatrics, Memorial Sloan Kettering Cancer Center | Dec 15, 2020 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 30, 2024 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | New York Genome Center | Jan 13, 2023 | The c.456+4A>T variant identified in FANCC has previously been reported as homozygous and compound heterozygous in multiple individuals with Fanconi anemia [PMID: 20301575] and determined as a pathogenic founder variant in the Ashkenazi Jewish population [PMID: 7492758]. Multiple independent laboratories have deposited this variant as Pathogenic in the ClinVar database (Variation ID: 12045). The c.456+4A>T variant is observed in 137 alleles (0.023% minor allele frequency with 0 homozygotes) in population databases (gnomAD v2.1.1 and v3.1.2, TOPMed Freeze 8), and this frequency is low enough to be consistent with a recessive carrier frequency. The c.456+4A>T variant is located in the splice region after exon 5 of this 15-exon gene and is predicted to affect mRNA splicing (Splice AI = 0.895). Functional studies demonstrated aberrant splicing and reduced DNA end-joining activity in patient-derived fibroblast cells carrying the c.456+4A>T variant [PMID: 8348157, 15364573]. Based on available evidence this inherited c.456+4A>T variant identified in FANCC is classified as Pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Feb 20, 2022 | - - |
| not provided, no classification provided | literature only | GeneReviews | - | Common in Ashkenazi Jewish; also reported in a Japanese cohort - |
| Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Oct 05, 2018 | The FANCC c.456+4A>T variant is a common pathogenic FANCC variant, particularly in the Ashkenazi Jewish population (Verlander et al. 1995; Auerbach, 2009). Across a selection of available literature, the c.456+4A>T variant has been identified in a homozygous state in 12 probands, in a heterozygous state in one proband in whom a second variant was not identified, and in a heterozygous state in seven unaffected family members (Whitney et al. 1993; Futaki et al. 2000; Auerbach, 2009). The c.456+4A>T variant was absent from 25 controls and is reported at a frequency of 0.006016 in the European (non-Finnish) population of the Genome Aggregation Database. Verlander et al. (1995) determined that the carrier frequency of the c.456+4A>T variant in the Ashkenazi Jewish population is approximately one in 89, or 1.1%. RT-PCR analysis indicated the c.456+4A>T variant disrupts splicing and results in the production of two abnormal products, an 111bp in-frame deletion and a 40bp partial removal of exon 4 (Whitney et al. 1993). Patient-derived fibroblasts demonstrated that the c.456+4A>T variant significantly reduced DNA end-joining activity compared with wild type cells (Donahue et al. 2004). Based on the evidence, the c.456+4A>T variant is classified as pathogenic for Fanconi anemia. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Nov 12, 2019 | NM_000136.2(FANCC):c.456+4A>T is classified as pathogenic in the context of Fanconi anemia. Sources cited for classification include the following: 8081385, 7492758, 8348157, 11427142, 9207444, and 10666230. Classification of NM_000136.2(FANCC):c.456+4A>T is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | Jul 02, 2018 | - - |
| Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 27, 2001 | - - |
not provided Pathogenic:4
| Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 06, 2022 | Canonical splice site variant demonstrated to result in an in-frame loss of exon 5 (Whitney 1993), which includes portions of the critical RED, FAZF, GRP94, and Hsp70 binding regions (Gordon 2000); Published functional studies demonstrate a damaging effect: decreased nuclear localization, p53 phosphorylation and binding to co-factors in response to drug-induced DNA damage (Loke 2015); Also known as IVS4+4A>T; This variant is associated with the following publications: (PMID: 22701786, 10666230, 26681312, 20301575, 30792206, 31513304, 8348157, 23613520, 26778106, 27619566, 26976241, 28301456, 28717661, 28495237, 27832981, 28425259, 28627524, 30683899, 30322717, 30676620, 20869034, 25236480, 7492758, 25545896, 30249500, 32570879, 30945166, 31558676, 25652403, 32235514, 8734810, 32885271, 34308366, 34426522, Gordon2000[Book]) - |
| Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Apr 07, 2015 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Dec 15, 2022 | In the published literature, the variant has been reported in individuals with Fanconi anemia type C (FA-C) (PMIDs: 31558676 (2020), 28425259 (2017), 23613520 (2013), 10666230 (2000), 9207444 (1997), 8639804 (1996), 7492758 (1995), 8128956 (1994)) and in individuals with various cancer types, including rhabdomyosarcoma (PMID: 34308366 (2021)), hereditary breast and/or ovarian cancer (PMIDs: 32885271 (2021), 32235514 (2020), 30322717 (2018), 26681312 (2015)), anaplastic astrocytoma (PMID: 32570879 (2020)), testicular cancer (PMID: 30676620 (2019)), melanoma (PMID: 26681312 (2015)) and pancreatic cancer (PMID: 26681312 (2015)). Functional studies have demonstrated this variant leads to exon skipping (PMID: 8348157 (1993)) and decreased DNA end joining ability (PMID: 15364573 (2004)). Additionally, this variant is a well-known founder variant in the Ashkenazi Jewish population (PMIDs: 10666230 (2000), 7492758 (1995), 8348157 (1993)). Analysis of this variant using software algorithms for the prediction of the effect of nucleotide changes on FANCC mRNA splicing yielded inconclusive findings. Based on the available information, this variant is classified as pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | Feb 11, 2015 | - - |
Fanconi anemia Pathogenic:3
| Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jan 19, 2024 | This sequence change falls in intron 5 of the FANCC gene. It does not directly change the encoded amino acid sequence of the FANCC protein. It affects a nucleotide within the consensus splice site. This variant is present in population databases (rs104886456, gnomAD 0.6%). This variant has been observed in individuals with Fanconi anemia (PMID: 8081385, 8348157, 10666230). It has also been observed to segregate with disease in related individuals. This variant is also known as IVS4+4A>T. ClinVar contains an entry for this variant (Variation ID: 12045). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
| Pathogenic, no assertion criteria provided | curation | Reproductive Health Research and Development, BGI Genomics | Jan 06, 2020 | NG_011707.1(NM_000136.2):c.456+4A>T is also known as IVS4+4A>T in literatures. It has an allele frequency of 0.006 in Ashkenazi Jewish subpopulation in the gnomAD database. Whitney et al reported that this variant resulted exon skipping due to abnormal gene splicing (PMID: 8348157). FANCC c.456+4A>T has been published in both the compound heterozygous and homozygous state in individuals with Fanconi Anemia (PMID: 8348157). It is also determined as a pathogenic founder variant in the Ashkenazi Jewish population(PMID: 7492758). Taken together, we interprete this variant as Pathogenic/Likely pathogenic. ACMG/AMP Criteria applied: PS3; PM3_Strong; PP4. - |
| Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Mar 17, 2017 | - - |
Malignant tumor of breast Pathogenic:1
| Pathogenic, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The FANCC c.456+4A>T variant was identified in 19 of 116 proband chromosomes (frequency: 0.16) from individuals or families with Fanconi Anemia (Whitney 1993, Futaki 2000). The variant was also identified in dbSNP (ID: rs104886456) as “With Pathogenic allele”, ClinVar and Clinvitae (8x classified as pathogenic by GeneDx, EGL Genetic Diagnostics, Invitae, Children's Mercy Hospital, Ambry Genetics, Counsyl, OMIM, Gene Reviews), and LOVD 3.0 (83 entries). The variant was not identified in the COSMIC or MutDB databases. The variant was identified in control databases in 73 of 276626 chromosomes at a frequency of 0.0003, increasing the likelihood this could be a low frequency variant in certain populations of origin (Genome Aggregation Database Feb 27, 2017). It was observed in the following populations: Other in 2 of 6450 chromosomes (freq: 0.0003), Latino in 1 of 34376 chromosomes (freq: 0.00003), European Non-Finnish in 9 of 126366 chromosomes (freq: 0.00007), and Ashkenazi Jewish in 61 of 10140 chromosomes (freq: 0.006), while the variant was not observed in the African, East Asian, European Finnish, or South Asian populations. In a study of carrier status of the American Ashkenazi Jewish population, 35 of 6208 chromosomes (freq. 0.006) were positive for this variant, which was not found in any of 1126 control chromosomes from the Iraqi Sephardic Jewish population. This variant is described as a founder mutation in the Ashkenazi Jewish population with a severe phenotype in Ashkenazi Jewish Fanconi Anemia (FA) patients, but a milder phenotype in Japanese FA patients, suggesting the presence of unidentified modifying factors (de Vries 2012, Futaki 2000). The pathogenic effect of this variant in FA is well described in the literature; however its role in cancer risk is less clear. An Israeli study of asymptomatic heterozygous carriers of this variant failed to demonstrate an increased risk of cancer; however the number of patients studied was relatively small and the average age was low at 31 years old (Laitman 2015). The c.456+4A>T variant is located in the 5' splice region but does not affect the invariant +1 and +2 positions. However, positions +3 to +6 are part of the splicing consensus sequence and variants involving these positions sometimes affect splicing. 3 out of 4 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) predict a greater than 10% difference in splicing. This variant has been shown to result in the skipping of exon 5 (Whitney 1993). In summary, based on the above information, this variant meets our laboratory’s criteria to be classified as pathogenic. - |
Hereditary cancer-predisposing syndrome Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 11, 2021 | The c.456+4A>T intronic pathogenic mutation results from an A to T substitution 4 nucleotides after coding exon 4 in the FANCC gene. This well-described mutation has been reported in multiple homozygous and compound heterozygous individuals with Fanconi anemia, and it is the most common mutation in FANCC in individuals of Ashkenazi Jewish descent (Whitney MA et al. Nat. Genet. 1993 Jun;4:202-5; Whitney MA et al. Hum. Mutat., 1994;3:339-41; Verlander PC et al. Am. J. Hum. Genet. 1994 Apr;54:595-601; Yamashita T et al. Blood. 1996 May;87:4424-32; Futaki M et al. Blood. 2000 Feb;95:1493-8; Kutler DI et al. Fam. Cancer. 2004;3:241-8; Chandrasekharappa SC et al. Blood. 2013 May;121:e138-4; Aftab I et al. Turk J Med Sci, 2017 Apr;47:391-398). This alteration was also identified in 7/10030 consecutive patients referred for evaluation by an NGS hereditary cancer panel (Susswein LR et al. Genet. Med. 2016 Aug;18:823-32). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site and may result in the creation or strengthening of a novel splice donor site. RNA studies have demonstrated that this alteration results in aberrant mRNA splicing (Whitney MA et al. Nat. Genet. 1993 Jun;4:202-5; Chandrasekharappa SC et al. Blood. 2013 May;121:e138-4). Of note, this mutation is also designated as IVS4+4A>T and c.711+4A>T in published literature. Based on the available evidence, this alteration is classified as a pathogenic mutation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
dbscSNV1_RF
Pathogenic
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_DG_spliceai
Position offset: 44
DS_DL_spliceai
Position offset: 4
Find out detailed SpliceAI scores and Pangolin per-transcript scores at